HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency by Schaller, Torsten et al.
HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear
Import Pathway, Integration Targeting and Replication
Efficiency
Torsten Schaller
1¤, Karen E. Ocwieja
2, Jane Rasaiyaah
1, Amanda J. Price
3, Troy L. Brady
2, Shoshannah L.
Roth
2, Ste ´phane Hue ´
1, Adam J. Fletcher
1, KyeongEun Lee
4, Vineet N. KewalRamani
4, Mahdad
Noursadeghi
1, Richard G. Jenner
1, Leo C. James
3, Frederic D. Bushman
2, Greg J. Towers
1*
1University College London Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, London, United Kingdom, 2University of
Pennsylvania School of Medicine, Department of Microbiology, Philadelphia, Pennsylvania, United States of America, 3Medical Research Council Laboratory of Molecular
Biology, Protein and Nucleic Acid Chemistry Division, Cambridge, United Kingdom, 4HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United
States of America
Abstract
Lentiviruses such as HIV-1 traverse nuclear pore complexes (NPC) and infect terminally differentiated non-dividing cells, but
how they do this is unclear. The cytoplasmic NPC protein Nup358/RanBP2 was identified as an HIV-1 co-factor in previous
studies. Here we report that HIV-1 capsid (CA) binds directly to the cyclophilin domain of Nup358/RanBP2. Fusion of the
Nup358/RanBP2 cyclophilin (Cyp) domain to the tripartite motif of TRIM5 created a novel inhibitor of HIV-1 replication,
consistent with an interaction in vivo. In contrast to CypA binding to HIV-1 CA, Nup358 binding is insensitive to inhibition
with cyclosporine, allowing contributions from CypA and Nup358 to be distinguished. Inhibition of CypA reduced
dependence on Nup358 and the nuclear basket protein Nup153, suggesting that CypA regulates the choice of the nuclear
import machinery that is engaged by the virus. HIV-1 cyclophilin-binding mutants CA G89V and P90A favored integration in
genomic regions with a higher density of transcription units and associated features than wild type virus. Integration
preference of wild type virus in the presence of cyclosporine was similarly altered to regions of higher transcription density.
In contrast, HIV-1 CA alterations in another patch on the capsid surface that render the virus less sensitive to Nup358 or
TRN-SR2 depletion (CA N74D, N57A) resulted in integration in genomic regions sparse in transcription units. Both groups of
CA mutants are impaired in replication in HeLa cells and human monocyte derived macrophages. Our findings link HIV-1
engagement of cyclophilins with both integration targeting and replication efficiency and provide insight into the
conservation of viral cyclophilin recruitment.
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Introduction
The ability to infect terminally differentiated cells of the
monocyte-macrophage lineage is a conserved property of lentivi-
ruses, including HIV-1 [1]. This process requires pre-integration
complexes (PICs) to traverse the nuclear pore, though the molecular
mechanism remains unclear. The HIV-1 proteins matrix, Vpr and
integrase, as well as a DNA triplex at the central polypurine tract,
have been proposed to contribute, but contrary evidence has been
presented for each [2–5]. Gammaretroviruses such as murine
leukemia virus (MLV) are dependent on cell division for infectivity
and infect non-dividing cells inefficiently [6]. Characterization of
HIV-1/MLV chimeric viruses has suggested a role for the HIV-1
capsid (CA) in nuclear entry [7]. Furthermore, certain HIV-1 CA
mutants are selectively defective in arrested cells but not in actively
dividingcellsagainimplicating a role forCAinHIV-1nuclearentry
[8–10].
The nuclear pore complex (NPC), through which HIV replication
intermediates must pass, consists of multiple copies of at least 30
different nuclear pore proteins (Nups). Nup358 is a large 358 kDa
protein that constitutes the cytoplasmic filaments and has a C-
terminal cyclophilin (Cyp) domain. It was first named Nup358 [11]
but has also been called RanBP2 [12]. We use its original name
Nup358 throughout this study. Several roles have been proposed for
Nup358 involving cell cycle control, nuclear export, and transpor-
tin/importin dependent nuclear import (reviewed in [13]). In
addition, Nup358 is a co-factor for HIV-1 replication, supporting
nuclear entry of viral PICs and influencing target site preference for
integration [14–17]. It has been unknown how the virus engages
Nup358 and influences PIC traffic across the nuclear pore.
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002439Here we demonstrate that HIV-1 CA binds directly to the
Nup358 Cyp domain (Nup358Cyp) with an affinity within three
fold of its binding of the monomeric cytoplasmic cyclophilin,
CypA, which is known to be important during HIV-1 infection.
We also demonstrate that CypA is important for directing HIV-1
into a nuclear entry pathway involving Nup358 and subsequent
engagement of the nuclear basket protein Nup153, ensuring
integration into preferred genomic loci. We report that altering
CA interactions with Nup358 or CypA results in alterations in
integration targeting preference, and reduced replication in
macrophages. Our study provides the first evidence for direct
interaction between HIV-1 CA and the NPC and suggests possible
models for links between nuclear import, integration site selection
and effective replication in primary human cells.
Results
Lentiviral Capsid Protein Determines Engagement of
Nup358/RanBP2
Several studies have shown that depletion of Nup358 reduces
HIV-1 infectivity. We sought to define the HIV-1 determinant
that confers its sensitivity to Nup358 depletion by studying
infections with VSV-G pseudotyped viral vectors encoding GFP.
Stable Nup358 depletion by transduction of HeLa cells with MLV
or HIV-1 based shRNA expression vectors reduced HIV-1 GFP
vector infectivity by 6- to 8-fold confirming Nup358’s role as an
HIV-1 cofactor [14,17] (Figure 1A, B and Figure S1). We
validated effective shRNA targeting by western blotting, using a
Nup358 specific antibody (Figure 1B), as well as by co-transfecting
the shRNA expression vector and a plasmid encoding GFP-tagged
Nup358 into 293T cells (Figure S2). Studies on the role of Nup358
in HIV-1 replication have used M-group HIV-1 isolates [14–17].
In order to confirm the importance of Nup358 as a cofactor for
other HIV-1 isolates we also tested the O-group HIV-1 virus
MVP5180 [18,19] as a distantly related HIV-1 and found that this
too was sensitive to Nup358 depletion, suggesting that Nup358 use
is a conserved feature of HIV-1 biology (Figure 1A and Figure
S1C). We next tested whether the even more distantly related
simian immunodeficiency virus from macaques (SIVmac) was
sensitive to Nup358 depletion. In contrast to HIV-1, infectivity of
SIVmac, was not reduced by Nup358 RNAi, suggesting species-
specificity of Nup358 use (Figure 1A and Figure S1C). We next
sought to identify the viral determinant for Nup358 RNAi
sensitivity. Given that the HIV-1 capsid protein (CA) has been
implicated in HIV-1 nuclear import [7,8,10], we tested whether
the different sensitivities to Nup358 depletion between HIV-1 and
SIVmac could be accounted by their different CA proteins. We
exchanged CA coding regions between HIV-1 and SIVmac and
analyzed infectivities of chimeric viruses on Nup358 depleted cells.
Replacement of SIVmac CA with CA from HIV-1 [20] rendered
the chimeric SIVmac sensitive to Nup358 depletion, while
replacement of HIV-1 CA with SIVmac CA [21] rendered
HIV-1 largely insensitive to Nup358 depletion (Figure 1C). For
comparison, we examined the sensitivity of these viruses to
transportin 3 (TRN-SR2) depletion, and confirmed that TRN-
SR2 specific shRNA reduced infectivity of both HIV-1 (,8 to 10-
fold) and SIVmac (,20-fold) (Figure 1A and Figure S1). MLV
GFP vector infectivity was not affected by depletion of these
proteins as reported previously, consistent with MLV’s inability to
traverse the nuclear pore and infect non-dividing cells (Figure 1A
and Figure S1).
If Nup358 and TRN-SR2 facilitate nuclear entry of wild type
HIV-1, then their depletion should inhibit HIV-1 infection at the
level of nuclear import. We confirmed that 2-LTR circle products
of HIV-1 were modestly reduced in abundance in the Nup358 or
TRN-SR2 depleted cells, whereas late reverse transcript produc-
tion was unaffected (Figure 1D) [22]. However, we observed that
the ten-fold reduction in infectivity was greater than the two to
four-fold reduction in 2-LTR circles, possibly explained by an
integration defect increasing the amount of 2-LTR circles. To
measure integration we infected Nup358 or TRN-SR2 depleted
cells with HIV-1 GFP vector, grew the cells for 2 weeks and
measured the number of integrated proviruses by Taqman qPCR.
We observed that the reduction of integrated proviruses in
Nup358 depleted cells (5-fold) was similar to the reduction of 2-
LTR circles (4-fold) (Figure 1D and Figure S3). In contrast, the
reduction of proviruses in TRN-SR2 depleted cells was signifi-
cantly greater (50-fold), than the reduction in 2-LTR circles (2 to
3-fold). This observations may suggest that Nup358 depletion
blocks HIV-1 at a step prior to nuclear import but after reverse
transcription, whereas TRN-SR2 depletion imposes two blocks,
one at the stage of nuclear import (reduction of 2-LTR circles)
and a second at integration. However, we suggest caution in
interpretation of 2-LTR circle assay as a measure of nuclear entry
given that 2-LTR circles are non productive for infection and
their formation may have different co-factor requirements.
Importantly, replication of wild type NL4.3GFP-IRES was also
impaired in Nup358 or TRN-SR2 depleted HeLa cells expressing
CD4 (Figure 1E). Equivalent CD4 expression in these cells was
confirmed by flow cytometry using fluorescent CD4 specific
antibody (Figure S4). These data suggest that Nup358 and TRN-
SR2 contribute to optimal viral nuclear entry, integration and
eventually replication.
Nup358 Interacts with HIV-1 CA via Its Cyclophilin
Domain
Nup358 contains a cyclophilin domain (Nup358Cyp) at its
extreme carboxyl-terminus. The HIV-1 N-terminal CA domain
(CA
NTD) resides on the surface of the virion core and recruits
CypA to viral cores [23,24]. The CA-dependent sensitivity of
HIV-1 to Nup358 depletion led us to hypothesize that HIV-1
CA
NTD might also interact with Nup358Cyp in a similar manner
Author Summary
During infection HIV-1 enters the nucleus by crossing the
nuclear membrane and incorporating itself into the host
DNA by a process called integration. Here we show that
the viral capsid protein gets tethered to a cyclophilin
protein called Nup358, a component of the nuclear
membrane gateways that allow transport between the
cytoplasm and the nucleus. Altering the capsid protein so
that it cannot use Nup358 prevents viral replication in
macrophages, a natural target cell type for HIV-1.
Intriguingly, these viral mutants are not less infectious in
certain immortalised cell lines suggesting that in these
cells nuclear entry is regulated differently. In this case
similar to wild type virus, the mutant viruses integrate into
host chromosomes but they integrate into different
regions suggesting that the pathway into the nucleus
dictates where the virus ends up in the host chromatin. We
also show that another cyclophilin, the cytoplasmic
protein cyclophilin A, influences the engagement of
Nup358 as well as other proteins involved in HIV-1 nuclear
entry. We hypothesise that HIV-1 has evolved to use
cyclophilins so that it can access a particular pathway into
the nucleus because alternative pathways lead to defects
in integration targeting and viral replication in human
macrophages.
Cyclophilins Mediate HIV-1 Nuclear Import
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NTD to Nup358 and effects on HIV-1 infectivity. A, VSV-G pseudotyped GFP encoding vectors derived from HIV-1
NL4.3 or MVP5180, SIVmac, or MLV were titered on HeLa cells expressing scrambled control (SC) or Nup358 or TRN-SR2 specific shRNA (mean and SD,
n=3). Relative changes from titer on control cells are shown above the bars. B, Western blots detecting Nup358, TRN-SR2 or b-Actin as loading
control. C, Schematic representation of HIV-1/SIVmac chimeras and titration of HIV-1 GFP vector bearing an SIVmac CA (HIV-1 SIVCA) or SIVmac
bearing HIV-1 CA-p2 (SIV(HIV-1CAp2)) measured on SC, Nup358, or TRN-SR2 depleted HeLa cells (mean and SD, n=3). D, Measurement of HIV-1 late
reverse transcription product (LRT) or 2-LTR circles at indicated time points post infection (p.i.) in HeLa control cells (SC) or cells depleted for Nup358
or TRN-SR2 (mean and SD, n=3). A parallel sample was used to determine the number of infected cells by flow cytometry 48 h post infection. E, HeLa
control cells (SC) or cells depleted for Nup358 or TRN-SR2 were transduced with an MLV vector expressing human CD4 and the neomycin resistance
gene and drug selected cell population were infected with NL4.3GFP-IRES. Percentage of infected cells was enumerated at indicated time points by
measuring GFP expression using flow cytometry. F, Isothermal titration calorimetry of cyclophilin A (CypA) or Nup358Cyp against the CA
NTD domains
of NL4.3 HIV-1 or SIVmac in the presence or absence of 10 mM cyclosporine (Cs). G, HIV-1 GFP vector titer on CRFK cells expressing empty vector (EV),
owl monkey TRIM5 RBCC fused to human CypA (TRIMCypA) or human Nup358Cyp (TRIMNup358) in the presence or absence of 5 mM Cs (mean and
SD, n=3). Protein levels measured by western blot detecting the HA tag with b-Actin as a loading control.
doi:10.1371/journal.ppat.1002439.g001
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CypA and Nup358Cyp and measured binding to recombinant
CA
NTD, using isothermal titration calorimetry (ITC) [25]. We
found that the HIV-1 CA
NTD bound Nup358Cyp with a Kd of
16 mM, in a similar range to its Kd of 7 mM for CypA (Figure 1F)
[25]. Surprisingly, the CypA inhibitor cyclosporine (Cs) did not
prevent Nup358Cyp binding to HIV-1 CA
NTD whereas it did
inhibit CypA binding. Whilst capsid interaction with both
Nup358Cyp and CypA was entropically favourable, interaction
with Nup358Cyp was more strongly entropically favourable than
CypA. This does not markedly alter the affinity with respect to
CypA as CA
NTD interaction with CypA is more enthalpically
favourable than with Nup358Cyp. The different thermodynamic
signatures between CypA and Nup358Cyp suggest that the two
proteins do not form identical interactions. The entropic
component of any interaction is the sum of changes in protein
and solvent dynamics. Given that the ligand, CA
NTD, is the same
in each experiment whilst Nup358Cyp and CypA comprise a
single globular fold it is likely that the entropically favourable
nature of both interactions is a consequence of releasing ordered
water molecules upon complex formation. The larger entropic
change associated with Nup358Cyp interaction may indicate a
greater release of ordered water upon complexation, suggesting
that the interface is larger than in CypA:capsid.
SIVmac CA
NTD did not bind Nup358Cyp (Figure 1F), and
bound CypA with a very low affinity (,800 mM) (Figure 1F),
which becomes important below. The inability of Nup358Cyp to
bind to SIVmac CA
NTD correlates with the insensitivity of
SIVmac to Nup358 depletion in HeLa cells (Figure 1A).
To probe Nup358Cyp binding further we designed an HIV-1
inhibitor based on the simian restriction factor TRIMCyp. Owl
monkey TRIMCyp blocks HIV-1 by binding incoming capsids via
its CypA domain [26]. We replaced the TRIMCyp cyclophilin
domain with human CypA or Nup358Cyp to make TRIMCypA
and TRIMNup358. We found that both TRIMNup358 and
TRIMCypA blocked HIV-1 infectivity (Figure 1G) whereas
SIVmac infection was not restricted, as expected from the lack
of binding (Figure S5). Importantly, Cs treatment only rescued
infectivity from TRIMCypA but not from TRIMNup358,
corroborating Cs sensitivity measured by ITC (Figure 1F). We
confirmed similar expression levels of chimeric proteins by western
blot (Figure 1G). These data are consistent with HIV-1, but not
SIVmac, CA
NTD efficiently binding Nup358Cyp in the context of
TRIMNup358 in the cytoplasm of infected cells. This suggests that
HIV-1 PICs containing CA or possibly entire capsid cores can
interact directly with a component of the NPC, providing insight
into how HIV-1 contacts the nuclear pore during the process of
nuclear entry.
Residue 61 of the Nup358 Cyclophilin Domain Is
Positively Selected
Host proteins that interact with pathogens are often under
positive selective pressure [27]. A higher rate of non-synonymous
nucleotide substitutions (dN) than synonymous substitutions (dS) at
a particular codon in an interspecies comparison provides
evidence for such positive selection. We aligned Nup358Cyp
DNA sequences from 12 different species (Figure S6) and
performed an analysis of codon-specific selective pressures using
the program Random Effect Likelihood (REL) implemented on
the online version of the HyPhy package [28]. Despite overall
strong negative selection across the Cyp domain, we found
Nup358Cyp codon 61 to be positively selected at a statistically
significant level (Bayes factor .50; Figure 2A). Indeed, residue 61
is extremely conserved as methionine across the whole vertebrate
Cyp family except in Nup358Cyp. (Figure 2B, C). In the case of
Nup358Cyp lower vertebrates encode the ancestral methionine,
whereas higher vertebrates encode valine, leucine or isoleucine at
this position. Fixation of the positively selected site appears to have
occurred after the divergence of fish and tetrapods, since
Nup358Cyp sequences from fish (e.g. Danio rerio) retain methionine
at position 61 (Figure 2B, C). This observation suggests that
Nup358 has been under selective pressure to evolve and that this
has led to variation in the sequence at this position. The
cyclophilin domain of Nup358 has been proposed to possess
prolyl cis-trans isomerase activity, similarly to CypA [29,30].
Assuming that the Nup358Cyp active site is homologous to that of
CypA then according to the CypA structure (PDB:1FGL) residue
61 is located directly at the bottom of the active site suggesting that
it might impact on substrate specificity (Figure 2D). To examine
this further we made a TRIMNup358 mutant in which the valine
at Nup358Cyp position 61 was changed to the ancestral residue
methionine. TRIMNup358 V61M was no longer able to restrict
HIV-1, suggesting that binding to HIV-1 CA is influenced by this
residue (Figure 2E). Our results suggest that during evolution
selective pressure, possibly from ancient pathogenic viruses, has
driven the change of Nup358Cyp position 61, altering substrate
specificity in higher vertebrates. In turn HIV-1 is adapted to use
this modified protein for nuclear entry in humans.
Substitutions in HIV-1 CA
NTD Alter Engagement of
Nup358/TRN-SR2
If binding of HIV-1 CA to Nup358 is important for HIV-1
infectivity, then amino acid substitutions in CA that affect
interaction with Nup358 should influence infectivity. Indeed, we
found that whilst wild type HIV-1 infectivity is sensitive to both
Nup358 as well as TRN-SR2 depletion, certain HIV-1 CA
mutants were not, suggesting an inability to utilize these cofactors.
We infected HeLa cells stably expressing Nup358 or TRN-SR2
shRNA with GFP-encoding VSV-G pseudotyped HIV-1 vectors
bearing wild type or mutant CA. We found that the cyclophilin-
binding mutants G89V and P90A were insensitive to Nup358
depletion but remained sensitive to TRN-SR2 depletion
(Figure 3A). We hypothesized that an inability to bind Nup358-
Cyp or CypA might underlie infectivity defects of other HIV-1 CA
mutants. The HIV-1 CA mutant N57A is more severely defective
in arrested cells than dividing cells (Figure 3A) [10], suggesting that
this residue may have a role in nuclear entry. Indeed, ITC
demonstrates that N57A is impaired in binding Nup358Cyp (Kd
55 mM) but not CypA (Kd 7 mM) (Figure 3B). As, N57A is less
sensitive to both Nup358 and TRN-SR2 depletion (Figure 3A), we
hypothesize that its infectivity defect is caused by an inability to
engage these proteins. We found that N57A was still restricted by
TRIMNup358 (Figure S5), suggesting that increased avidity
through Nup358Cyp dimerization in the context of TRIMNup358
may overcome the reduced affinity to monomeric Nup358Cyp.
Importantly, N57A’s insensitivity to Nup358 depletion suggests that
it does not engage Nup358 during nuclear entry.
Finally, we studied the HIV-1 CA mutant N74D, which is
reported to be less sensitive to Nup358 or TRN-SR2 depletion
(Figure 3A) [17,31]. Like N57A, N74D bound monomeric
Nup358Cyp in ITC experiments with significantly lower affinity
than wild type (Kd 95 mM) (Figure 3B) and like N57A, N74D was
also restricted by TRIMNup358 (Figure S5A). As for N57A, it
seems contradictory that HIV-1 CA mutants that are less sensitive
to Nup358 depletion are restricted by TRIMNup358. We assume
that binding characteristics of TRIMNup358, and Nup358 itself,
to CA are different particularly given that TRIM5 is reported to
form cytoplasmic dimers [32] and higher-order multimers [33],
Cyclophilins Mediate HIV-1 Nuclear Import
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TRIM5a, could increase binding of Nup358Cyp to CA by
increasing avidity, thereby allowing restriction. In addition, it is
possible that the decreased binding of N57A as well as N74D to
TRIMNup358 is disguised by an increased sensitivity to restriction
by this TRIM5 chimera. HIV-1 CA N57 is located at the base of
helix 3 and N74 in helix 4 (Figure 4C, D), suggesting that amino
acid residues outside the Cyp-binding loop can impact on
Nup358Cyp binding. We propose that Nup358 and TRN-SR2
define an import pathway used by wild type HIV-1 and that
CA amino acid substitutions direct the virus to use Nup358
independent (G89V, or P90A), or Nup358/TRN-SR2 indepen-
dent (N74D, or N57A) import pathways.
To test whether HIV-1 dependence on Nup358 is increased in
non-dividing cells, we arrested HeLa cells with aphidicolin and
measured infectivity of the CA mutant viruses. We found that only
N57A and MLV infectivities were inhibited by aphidicolin
treatment (Figure 3A and Table S1) whereas mutants G89V,
P90A and N74D were not affected. This suggests that G89V,
P90A and N74D use Nup358/TRN-SR2 independent routes into
the nucleus even in the absence of cell division. This hypothesis is
supported by the observation that neither the wild type virus nor
these mutants become additionally sensitive to Nup358 or TRN-
SR2 RNAi in aphidicolin-arrested cells (Figure 3A and Table S1).
On the other hand N57A is slightly increased in its sensitivity to
aphidicolin particularly after Nup358 depletion. We conclude that
these co-factors are required for HIV-1 infection of dividing and
non-dividing cells.
Nup358/TRN-SR2 Independent HIV-1 CA Mutants
Integrate with Different Integration Site Preferences
HIV integration is favored in chromosomal regions rich in
genes and associated features such as CpG islands, DNAaseI
hypersensitive sites, and high G/C content. We have shown that
Nup358 or TRN-SR2 depletion reduces HIV-1 integration
frequency near these features [16]. To test this for the CA
mutants studied above, we sequenced 19,546 unique integration
sites from HIV-1 and its mutants by 454/Roche pyrosequencing
and compared their chromosomal distributions as described
[16,34–37].
Although the HIV-1 CA mutants retained the preference for
integration within transcription units, their integration site distri-
butions diverged from wild type HIV-1. The patterns clustered into
two groups that map to two distinct areas on the CA surface
(Figure 4). HIV-1 CA mutants N57A and N74D integrated into
regions of chromatin associated with a significantly lower density of
transcription units and associated features. For wild type HIV-1 this
density was 15 transcription units/MB, whereas for CA mutants
N57A or N74D the density was reduced to what is expected for
random integration (7–9 transcription units/MB) (Figure 4A and
Figure S7). In contrast, the two Cyp-binding mutants, G89V and
P90A, exhibited an opposite phenotype, with favored integration
into regions of increased density of transcription units (,20
transcription units/MB). The chimeric HIV-1 containing SIVmac
CA, showed a further increased preference for regions dense in
transcription units (25 transcription units/MB) (Figure 4A and
Figure S7A). These latter three viruses similarly showed increased
frequency of integration in areas rich in active genes, CpG islands,
DNase sites, and high in GC content, features correlating with high
gene density. Hierarchical clustering of the CA mutants based on
these data separated the viruses into two groups: N57A and N74D,
and the Cyp-binding mutants G89V, P90A and chimeric HIV-
1(SIVCA) (Figure 4B). Wild type HIV-1, which has an intermediate
targeting phenotype, was an outlier within this second group. Thus
amino acid substitutions in CA can alter integration targeting
preference, resulting in either of two phenotypes. Because G89V
and P90A influence targeting in the same direction, we infer that
disruption of normal CypA interactions, and possibly Nup358
interactions, result in increased frequency of integration in regions
with high densities of transcription units. The N74D and N57A
substitutions are less sensitive to depletion of both Nup358 and
TRN-SR2, and N74D gains sensitivity to depletion of other nuclear
pore proteins [17]. We thus infer that this pathway leads to favored
integration in regions with lower densities of transcription units.
We were surprised that HIV-1 CA mutants P90A and N74D,
which are less sensitive to depletion of TRN-SR2 and/or Nup358
(Figure 3A), and have different integration site preferences in
unmodified cells (Figure 4), were as infectious as wild type virus in
single round assays. This is true when the virus is pseudotyped
with the VSV-G envelope (Figure 3A) or the natural HIV-1 gp160
envelope (Figure S9). To test whether these CA substitutions affect
HIV-1 replication we compared replication of wild type HIV-1
NL4.3 (Ba-L Env) with CA mutants P90A and N74D in spreading
infection in HeLa TZM-bl cells [38]. Interestingly, we found that
replication of both HIV-1 CA mutants was impaired in these cells
compared to wild type virus, suggesting that cofactors used for
nuclear entry and/or integration site selection are important for
optimal replication (Figure 4E). We also found that HIV-1 NL4.3
(Ba-L Env) bearing CA alterations N74D or P90A replicated
poorly in primary human MDM from four independent donors,
whereas wild type virus replicated efficiently (Figure 4F and Figure
S7B). These data demonstrate that HIV-1 CA mutants P90A and
N74D do not support optimal replication. One possible explana-
tion is that this is due to differences in their integration site
targeting as compared to the wild type virus, though other models
are possible. Whether the defect in replication is due to a defect in
viral gene expression remains unclear. However, it is clear that the
mutant viruses that are unable to effectively utilize Nup358 or
TRN-SR2 display a replication defect in a cell line and in primary
human macrophages.
CypA-CA Interactions Dictate the Use of a Nup358/
Nup153 Dependent Nuclear Entry Pathway
The observation that HIV-1 CA mutants P90A and G89V, as
well as chimeric HIV-1(SIVCA) integrate into genome regions
with higher densities of transcription units and associated features
Figure 2. Nup358Cyp evolved under positive selection pressure. A, Codon positions under positive (dN.dS) and negative (dN,dS)
selection along the Nup358Cyp gene sequence, as indicated by the Bayesian probability that a particular site is under selective pressure. A Bayes
factor .50 is considered strong evidence for the favored model. B, Maximum likelihood phylogenetic tree of cyclophilins A, B, C, D, E, F, G, H and
Nup358Cyp from Rhesus macaque (M. mulatta), Human (H. sapiens), Chimpanzee (P. troglodytes), Dog (C. familiaris), Cow (B. taurus), Horse (E.
caballus), Marmoset (C. jacchus), Mouse (M. musculus), Rat (R. norvegicus), Opossum (M. domestica), Zebrafish (D. rerio), Orangutan (P. abelii) and
Rabbit (O. cuniculus). Branch lengths and bootstrap supports are shown. C, Maximum likelihood phylogenetic tree demonstrating the simplest model
of evolution of residue 61 in Nup358Cyp sequences. D, Structure of CypA bound to CA
NTD with CypA key residues R55 and M61 as well as HIV-1 CA
P90 highlighted. (PDB:1FGL) E, NL4.3 HIV-1 GFP vector titer on CRFK cells expressing empty vector (EV), TRIMCypA, wild type TRIMNup358, or
TRIMNup358 mutant V61M. Protein levels measured by western blot detecting the HA tag with b-Actin as loading control are shown. The data are
representative of three independent experiments (mean and SD, n=3).
doi:10.1371/journal.ppat.1002439.g002
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enced by CypA binding to CA. Since cyclosporine (Cs) selectively
inhibits CypA but not Nup358Cyp binding (Figure 1F, G), we
investigated whether Cs could retarget integration by HIV-1. In
fact, Cs treatment retargeted viral integration preferences in a
way that phenocopied the CA G89V/P90A substitutions shifting
integration preferences into regions of higher gene density
(Figure 5A, B). Thus preventing CypA-CA interactions with Cs
has the same effect on integration targeting as amino acid
substitutions in HIV-1 CA that block CypA binding, supporting
the idea that integration targeting is truly affected by cyclophilin-
CA interactions.
Figure 3. Effect of CA mutants on Nup358/TRN-SR2 RNAi sensitivity and Nup358Cyp binding. A, Titers of VSV-G pseudotyped NL4.3 HIV-
1 GFP vectors bearing wild type or mutant CA on HeLa control cells (SC), or Nup358 or TRN-SR2 depleted cells in the presence or absence of 2 mg/ml
aphidicolin (AC). MLV GFP vector was used as a control for aphidicolin. Relative changes from titer on control cells are shown above the bars. The data
are representative of two independent experiments each using three different virus doses. B, ITC of human CypA and Nup358-Cyp against HIV-1
CA
NTD mutants. Kd values as well as stoichiometries (N), enthalpies (DH) and entropies (DS) are shown.
doi:10.1371/journal.ppat.1002439.g003
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PLoS Pathogens | www.plospathogens.org 7 December 2011 | Volume 7 | Issue 12 | e1002439Figure 4. Residue changes in HIV-1 CA mutants alter integration site targeting. A, Effects of CA mutants on integration frequency near
multiple chromosomal features. The rows show genomic features, and the columns indicate integration site data sets. The color code indicates ROC
areas [34]. The arrow denotes the wild type control set used for pairwise statistical comparisons to the other data sets. P values summarizing the
significance of departures from the control are represented by asterisks (*P,0.05; **P,0.01; ***P,0.001). Several different intervals are compared.
"Expression density" summarizes the density of genes in the indicated length intervals that are expressed in the upper half ("top 1/2") or upper
sixteenth ("top 1/6") of all genes on Affymetrix HU95A chip data for HeLa cells (accessions GSM23372, GSM23373, GSM23377, and GSM23378). For a
more detailed guide see [16]. B, ROC area values were used to generate pairwise Euclidean distances, which were then analyzed by hierarchical
clustering generating the presented dendogram. The locations of changed residues in mutant viruses studied on C, the CA hexamer (PDB:3GV2) and
D, the CA monomer (PDB:3GV2). E, Time course of replication competent NL4.3 (Ba-L Env) bearing wild type, P90A or N74D CA in HeLa TZM-bl cells.
Luciferase expression was measured by counting RLU at indicated times after virus inoculation. The data are representative of two independent
experiments. F, Replication assay of NL4.3 (Ba-L Env) bearing wild type or CA mutants P90A or N74D in human MDM. Cells were stained for Gag p24
at specific time points after infection and infected colonies counted. Standard errors of the mean of three fields are shown.
doi:10.1371/journal.ppat.1002439.g004
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gene density/activity regions [16] but preventing CypA binding
by CA amino acid substitutions (G89V/P90A) or Cs treatment
shifted virus integration preferences into high gene density/activity
regions. This suggested to us that Nup358 and CypA have different,
possibly opposing effects on HIV-1. Alternately, Cs treatment
may somehow change the availability of Nup358 in the cell. To
investigate this further we tested whether CypA inhibition in
Nup358 depleted cells influences HIV-1infectivity. Remarkably, Cs
treatment specifically rescued HIV-1 infectivity reduced by Nup358
depletion to the level observed in controlcells (Figure 6A and Figure
S8). We note that the small inhibitory effect of Cs on HIV-1
infectivity is preserved and infectivity is rescued to the level of
infectivity on control cells treated with Cs. Thus Cs inhibits HIV-1
GFP infectivity by 2–3 fold but concomitantly rescues infectivity
from the effects of Nup358 depletion. Transient CypA depletion
using shRNA expression had a similar effect as CypA inhibition with
Cs, also rescuing infectivity reduced by Nup358 depletion
(Figure 6B). As expected, the CypA insensitive mutants G89V or
P90A did not respond significantly to Cs treatment or CypA
depletion by RNAi respectively (Figure 6A, B). The infectivity of the
HIV-1 CA mutant N74D was slightly reduced by Cs consistent with
its reduced sensitivity to Nup358 depletion and supporting the
notion that it is still able to recruit CypA as confirmed by ITC
(Figure 3B, 6A and Figure S8). Cs also partially rescued HIV-1
infectivity in cells with strong TRN-SR2 depletion (Figure 6A and
Figure S8), suggesting that TRN-SR2 participates in the Nup358
dependent importpathway into which the virus is directed byCypA.
We were also able to show that the distantly related HIV-1 O-
group virus MVP5180 was also specifically rescued upon Cs
treatment/CypA depletion in Nup358 or TRN-SR2 depleted cells
but was unaffected in control cells (Figure 6A, B). This suggests
that MVP5180 functionally interacts with CypA in a similar way to
NL4.3 and this is concordant with the very similar co-crystal
structures of M-group HIV-1 CA
NTD with CypA and O-group
HIV-1 CA
NTD with CypA (PDB ID: 1M9D) [39]. Together these
observations made using both NL4.3 and MVP5180 suggest that
CypA acts upstream of Nup358 and that Nup358 is not required for
HIV-1infectivity inthe absence of CypA activity. In otherwords we
propose that CypA activity directs the virus to engage Nup358.
If CypA activity directs HIV-1 to interact with cytoplasmic
Nup358 to traverse the NPC then reduced HIV-1 infectivity
through depletion of nuclear pore proteins that act downstream of
Nup358 should also be rescued by CypA inhibition. To test this we
analyzed infectivity of HIV-1 NL4.3 and its CA mutants in HeLa
cells depleted for Nup153 (Figure 6C). Nup153 is a NPC
component in the nuclear basket and has been highlighted in
genome wide siRNA screens as co-factor for HIV-1 [14,40,41].
We found that HIV-1 NL4.3 infectivity was strongly reduced in
Nup153 depleted cells by ,10-fold, whereas MLV infection was
not affected (Figure 6C). However, the Cyp non-binding mutant
HIV-1 CA G89V as well as mutants N74D and N57A, which are
less dependent on Nup358/TRN-SR2 were only moderately
affected (,3-fold). When cells were treated with Cs during
infection, infectivity reduced by Nup153 depletion was specifically
rescued for wild type virus, whereas the HIV-1 CA mutants
remained unaffected (Figure 6C). The O-group HIV-1 MVP5180
was affected by Nup153 depletion similarly to NL4.3 and CypA
inhibition rescued its infectivity similarly to what we observed in
Nup358 depleted cells. These observations support the notion
that inhibition of CypA recruitment leads HIV-1 to use different
cellular cofactors, and perhaps a different pathway, for nuclear
entry.
Importantly, Cs treatment prevented spreading infection of
wild type HIV-1 in human MDM [42](Figure 6D). Thus,
productive infection in a biologically relevant cell type is
dependent on the conserved use of cyclophilins. Our results
suggest that inhibition of CypA may not only prevent the use of
Nup358 but rather may direct HIV-1 into a Nup358/Nup153
independent nuclear entry pathway that may not be available or
functional in MDM. In one possible model, for some cell lines such
as HeLa cells, the use of alternate pathways and retargeting of
integration preferences may not lead to large infectivity defects
particularly when measuring infectivity using VSV-G pseudotyped
HIV-1 vectors with GFP driven from a heterologous promoter. In
replication assays using full length HIV-1 and primary targets of
HIV-1 infection such as macrophages, Cs treatment (Figure 6D) or
CA residue changes (Figure 4F) have their strongest inhibitory
effects. Whilst our observations can be explained by various
models, they support the notion that the cofactors that the virus
has evolved to use, and has conserved the use of, such as Nup358
and TRN-SR2, may be most important in the primary cells in
which the virus naturally replicates. A model is presented in
cartoon form (Figure 7).
Figure 5. CypA inhibition alters HIV-1 integration site targeting. A, Effects of CypA inhibition by cyclosporine (Cs) on integration frequency
near multiple chromosomal features for wild type NL4.3 HIV-1 GFP vector and CA mutants. The arrow denotes the wild type control set used for
pairwise statistical comparisons to the other data sets. The heat map analysis was performed as in Figure 4A. B, ROC area values were used to
generate pairwise Euclidean distances, which were then analyzed by hierarchical clustering generating the presented dendogram.
doi:10.1371/journal.ppat.1002439.g005
Cyclophilins Mediate HIV-1 Nuclear Import
PLoS Pathogens | www.plospathogens.org 9 December 2011 | Volume 7 | Issue 12 | e1002439Discussion
Here we have presented data suggesting that HIV-1 uses a
pathway that includes the cytoplasmic cyclophilin CypA and the
nuclear pore associated cyclophilin Nup358 to access the nucleus
and target preferred regions of the genome for integration. We
find that a determinant for the use of this pathway is CA and we
demonstrate the first direct interaction of HIV-1 CA with a
Figure 6. CypA inhibition forces HIV-1 into a Nup358/Nup153 independent nuclear entry pathway. A, Titers of VSV-G pseudotyped
NL4.3 HIV-1 GFP vectors bearing wild type or mutant CA on HeLa control cells (SC), or Nup358 or TRN-SR2 depleted cells in the presence or absence
of 8 mM Cs (mean and SD, n=3). Relative changes from titer on control cells are shown above the bars. B, HeLa cells expressing scrambled control
(SC), or Nup358 specific shRNA were transiently transduced with either MLV empty vector control or vector expressing CypA specific shRNA and
subsequently infected with wild type NL4.3 HIV-1 GFP vector or CA mutant P90A or O-group MVP5180 GFP vector. Infection was measured 48 hours
later by FACS to enumerate infected cells. Fold changes to control cells are shown. A parallel western blot for experiments in B detecting CypA and b-
Actin as loading control. C, HeLa control cells (SC) or transiently Nup153 depleted cells were infected with indicated vectors in the presence or
absence of 8 mM Cs (Mean and SD, n=3). Western blot detecting Nup153 and b-Actin as a loading control. D, MDM from 2 independent donors were
infected with 400 pg RT replication competent HIV-1 NL4.3 (Ba-L Env) in the presence of 5 mM Cs or DMSO. Replication was measured over time by
counting CA positive cells after staining with a CA specific antibody.
doi:10.1371/journal.ppat.1002439.g006
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of CypA/Nup358 by mutating CA or inhibiting CypA with Cs
appears to cause HIV-1 to use a Nup358/Nup153 independent
pathway. The role of CypA in this process remains obscure but
our data suggests that it directs HIV-1 to utilize a nuclear entry
pathway involving Nup358 and Nup153. Indeed, roles for CypA
in nuclear transport of cellular factors have been proposed before
[43–45]. Our data illustrate that this HIV-1 nuclear import
pathway is directly linked to integration site preference, which
provides a candidate explanation for reduced replication in human
MDM. Intriguingly, HIV-1 CA substitutions can influence the
regions of the genome that the virus targets for integration. We
have distinguished between the regions targeted for integration
using criteria related to the density of transcription units, including
GC content, DNAaseI hypersensitivity and gene expression.
Infections with HIV-1 variants containing substitutions in CA
that prevent CypA binding (e.g. G89V), and inhibiting CypA
binding with Cs, both lead to increased frequency of integration in
regions with higher densities of transcription units (Figure 4 and 5),
supporting the consistency of our observations. Furthermore,
mutations that render HIV-1 less sensitive to both Nup358 and
TRN-SR2 depletion (CA N57A and N74D) both shift integration
preferences to regions with lower densities of transcription units
(Figure 4). Thus mutations that prevent HIV-1 utilizing Nup358
and TRN-SR2 have the same effect as depletion of these proteins,
as described in our previous study [16]. These observations suggest
that nuclear entry pathways may lead to different areas of
chromatin and provide probes to investigate this possibility.
Several reports have suggested a role for HIV-1 CA in nuclear
entry [7,8,10,17,40,46]. Using ITC experiments we demonstrate
here that HIV-1 binds to the nuclear pore through interactions
between CA and the C-terminal Cyp domain of Nup358. This is
the first direct evidence for an interaction between CA and the
NPC and suggests that CA-containing PICs or whole capsid cores
dock at the NPC prior to nuclear entry as previously inferred from
microscopy studies [47]. Recruitment of cores through Nup358
may assist appropriate uncoating and interaction of PICs with
the nuclear transport machinery including TRN-SR2 and
Nup153. Remarkably, Nup358Cyp shows evidence for positive
selection and a positively selected residue affects restriction by
TRIMNup358 suggesting that this residue impacts on HIV-1 CA
binding. This is the first case of an HIV-1 co-factor displaying
signs of positive selection. We speculate that ancient pathogens,
possibly viruses, may have provided the necessary selective
pressure for the change of residue 61 from methionine, which
has been conserved in the entire cyclophilin family, to valine,
isoleucine or leucine in Nup358Cyp. It will be interesting to
examine whether other viruses that encounter the nucleus during
Figure 7. Model for CypA-dependent/-independent HIV-1 nuclear entry pathways. A, Wild type (WT) HIV-1 capsids are bound by
cytoplasmic cyclophilin A (CypA) molecules that direct the capsid to use a specific nuclear entry pathway. The nuclear entry pathway involves CA
binding to the cyclophilin domain of the cytoplasmic nuclear pore complex (NPC) component Nup358. Nup358 may mediate uncoating directly at
the nuclear pore, liberating the pre-integration complex, which will interact with TRN-SR2 and the nuclear NPC component Nup153. B, Inhibition of
CypA-CA interaction by the drug cyclosporine (Cs) or by substitution of CA residues that abolish CypA binding directs the virus into a less productive
CypA-independent nuclear entry pathway that displays impaired dependence on Nup358 and Nup153. This route of nuclear entry results in virus
integration preferences in areas of higher density of transcription units and associated features. C, HIV-1 capsid mutants that are less sensitive to
Nup358, Nup153 or TRN-SR2 RNAi (HIV-1 CA N57A or N74D) enter the nucleus through a different pathway that directs their integration into genome
areas of lower density of transcription units. D, Depletion of Nup358 by RNAi reduces viral nuclear entry via the Nup358-dependent pathway and the
virus gains access via an Nup358-independent alternative pathway resulting in phenotypically similar integration site selection as observed for the CA
mutants N74D or N57A. Alternative nuclear entry pathways disturb HIV-1 integration site selection, possibly contributing to sub-optimal replication
of the virus in spreading infection assays.
doi:10.1371/journal.ppat.1002439.g007
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their recruitment. Indeed, Nup358 has been suggested to be
involved in HSV-1 capsid attachment to the nucleus, however the
viral determinants for this process remain obscure [48].
We also demonstrate that HIV-1 CA sequence influences the
sites in which HIV-1 integrates. Although there are many possible
explanations for that, we hypothesize that this occurs through
selection of the cofactors for nuclear import or the nuclear import
pathway. In the future, it will be interesting to investigate whether
TRN-SR2 functions to enhance cytoplasmic availability of HIV-1
co-factors required for nuclear import or integration site selection.
Interaction with such co-factors may be disturbed by CA
mutations leading to impaired nuclear import or integration.
Surprisingly SIVmac, a primate lentivirus from rhesus ma-
caques that was derived experimentally from SIV from sooty
mangabeys [49] does not appear to utilize Nup358 during
infection. SIVmac is however sensitive to TRN-SR2 depletion
suggesting that it uses a related but somewhat different set of co-
factors to enter the nucleus as compared to HIV-1. SIVmac is
known to integrate into genes in a similar way to HIV-1 but subtle
differences between HIV-1 and SIVmac integration targeting may
exist. The significance of these observations remains unclear and
characterization of the pathways used by a variety of lentiviruses to
enter the nucleus and target favored sites will undoubtedly be
informative.
Whilst our data don’t rule out partial cytoplasmic uncoating we
envisage the HIV-1 CA acting as a protective cage around the
reverse transcription complex, shielding the viral macromolecules
from pattern recognition by innate immune mediators present in
the cytoplasm. Antagonistic Nup358 and CypA activities could be
explained by a model in which CypA stabilizes or protects the core
[50], whilst Nup358 regulates uncoating at the nuclear pore [47].
In this regard Nup358 binding to the conical viral core could have
different effects from monomeric CypA, as eight Nup358 proteins
are attached to the NPC [51]. Multiple simultaneous Nup358-CA
interactions might destabilize the HIV-1 core and liberated PICs
could then interact with TRN-SR2 and the nuclear located
Nup153 ensuring transport through the NPC to appropriate sites
[52]. This model provides a rationale for conservation of Cyp
binding and explains how CA might influence TRN-SR2 or
Nup153 usage without direct interaction [22,40,46,52]. This
model may also explain how the use of TRN-SR2 does not
correlate with the ability of various integrase proteins to bind
TRN-SR2 protein in vitro [46]. If lentiviruses regulate uncoating
through interactions between CA and other host factors then their
integrase proteins may be exposed to different karyopherins during
this process. In this way the CA sequence and structure might be a
stronger influence on the choice of karyopherins than integrase
despite integrase being the ultimate target for karyopherin
interaction. The Nup358 cyclophilin domain has been suggested
to act as a chaperone by mediating prolyl cis-trans isomerization of
cellular proteins [29,30]. It will be interesting to investigate
whether Nup358 is enzymatically active on the HIV-1 capsid core
and whether this causes uncoating at the nuclear pore.
Currently available cyclosporins do not antagonize Nup358Cyp
binding to HIV-1 CA but the fact that cyclophilins can be
pharmacologically inhibited suggests the possibility of specifically
inhibiting HIV-1 CA-Nup358Cyp interaction and possibly HIV-1
replication. Overall, our data demonstrate that rather than being
lost during cytoplasmic uncoating, HIV-1 CA binds to the nuclear
pore component Nup358 and directs the virus into a pathway that
regulates its traffic between the cytoplasm and chromatin, playing
a key role in the integration site targeting required for optimal
continuation of the viral replication cycle.
Materials and Methods
Viruses, Vectors and Infection Assays
VSV-G pseudotyped vectors derived from HIV-1, SIVmac and
MLV-B have been described as has their preparation by 293T
transfection [53]. The HIV-1/SIVmac chimeric vectors have been
described [20,21] as has the HIV-1 vector encoding MVP5180
Gag [19]. HIV-1 NL4.3GFP-IRES has been described [54]. Viral
doses were measured by reverse transcriptase (RT) enzyme linked
immunosorbant assay (Roche). Viral vector infection assays using
VSV-G pseudotyped viruses encoding GFP were analyzed by
enumerating the number of green cells 48 hours post infection by
flow cytometry. Viral vector infectivity experiments were per-
formed in a 24-well plate format as described [53]. To measure
late RT products, 2-LTR circles and integrated provirus, control
or shRNA expressing cells were infected with VSV-G pseudotyped
HIV-1 GFP encoding vector and then grown for indicated times.
Total DNA was purified from 2 samples at each time point
(QiaAmp, Qiagen) and 600 ng were subjected to Taqman
quantitative PCR using late RT [55], 2-LTR circle [56] or GFP
[53] primers and probe to detect provirus as described. Infectivity
was measured in parallel samples by flow cytometry 48 hours post
infection.
Replication Assay in Human Monocyte Derived
Macrophages (MDM) and TZM-bl Cells
MDM were prepared from fresh blood from healthy volunteers
as described [57]. Cells were infected with 400 pg RT/well in 24-
well plates and subsequently fixed and stained using a CA specific
antibody (CA183) and a secondary antibody linked to beta
galactosidase as described [57]. For measuring the effect of CypA
inhibition on HIV-1 replication the assay was performed in the
presence of 5 mM DMSO or Cs throughout the whole time course.
TZM-bl infection assay was performed with 50 pg RT/20000 cells
in 24-well plate dishes and RLU were measured at indicated time
points.
Integration Site Sequencing
Methods for integration site sequencing and heat map and
dendogram analysis have been described [16].
RNAi, Antibodies and Drugs
All RNA interference experiments were performed by expressing
short hairpin RNA from either MLV vector pSIREN RetroQ
(Clontech) (for Nup358, TRN-SR2 and Nup153) or pSUPER
(Oligoengine) (for CypA) or if indicated from the HIV-1 vector
pCSRQ, which was derived by subcloning the shRNA expression
cassette from pSIREN RetroQ into pCSGW. The CypA shRNA
target sequencehasbeen described [58].The Nup358 shRNA target
sequence that was used throughout the study was 5-GCGAAGT-
GATGATATGTTT-3. Nup153 shRNA target sequence was 5-
CAATTCGTCTCAAGCATTA-3. Both sequences were selected
as1ofthe4targetsequencesfromtheDharmaconsiRNAsmartpool
for Nup358 or Nup153, respectively. Both shRNAs had only minor
toxic effects on the cells, unlike shRNAs derived from the other three
target sequences of each smart pool (Figure S1A, and data not
shown). Additional Nup358 shRNA target sequences used in the
experiment shown in Figure S1A were shRNA2 5-CAAACCACG-
TTATTACTAA-3, shRNA3 5-CAGAACAACTTGCTATTAG-3
and shRNA4 5-GAAGGAATGTTCATCAGGA-3. Specificity for
each target sequence was confirmed by BLAT (UCSC genome
browser). For Nup358, we confirmed effective targeting by co-
transfecting the shRNA expression vector with a plasmid encoding
GFP-tagged Nup358 (Figure S2), as well as by western blotting using
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and control have been described and were also validated by co-
transfecting a plasmid encoding for TRN-SR2-IRES-eGFP with the
expression vectors encoding shRNA or control (SC) (Figure S2) [22].
The observations made for shRNA expressing HeLa cells were
similar between populations of puromycin selected cells and clonal
cells but the phenotype of cell clones was more stable, thus we used
single cell clones for all experiments (Figure S1A, B and data not
shown). Nup358, TRN-SR2, Nup153, CypA and beta-Actin were
detected by western blot using a Nup358 antibody kindly given by
Frauke Melchior, mouse TRN-SR2 antibody ab54353 (Abcam),
mouse Nup153 antibody ab24700 (Abcam), rabbit CypA antibody
SA296 (Biomol) and mouse beta-Actin antibody ab6276 (Abcam)
and appropriatehorseradishperoxidase linkedsecondaryantibodies.
TRIMCypA and TRIMNup358 were detected using anti-HA
antibody 3F10 (Roche). Cyclosporine (Sandoz) and aphidicolin
(Sigma) were diluted in DMSO and used at 5–8 mM and 2 mg/ml,
respectively.
Binding Assays and Positive Selection Analysis
Isothermal titration calorimetry was performed as described
[25].
Positive Selection Analysis
Codon-specific selection analysis was performed using the
Random Effect Likelihood (REL) algorithm as described [27]
using the alignment in Figure S6.
Supporting Information
Figure S1 Effects of Nup358 and transportin 3 RNAi on
HIV-1 infectivity. A, HeLa cells transiently transduced with the
MLV vector pSIREN-RetroQ expressing four different shRNAs
were infected in parallel with HIV-1 or MLV GFP encoding
vector and infectious units per milliliter viral supernatant were
determined. The target sequences for each shRNA were derived
from the Dharmacon Smartpool. Three of the four shRNA vectors
tested were cytotoxic and reduced MLV infectivity significantly.
Vector encoding Nup358 shRNA1 was used for further experi-
ments. B, NL4.3 derived VSV-G pseudotyped HIV-1 GFP vector
was titrated on cell populations transiently transduced with
lentiviral shRNA expression vectors CSRQ encoding scrambled
control (SC), transportin 3 (TRN-SR2) or Nup358 specific shRNA
and infectious units per ng RT were determined. C, VSV-G
pseudotyped GFP encoding vectors derived from NL4.3 HIV-1,
SIVmac, HIV-1 MVP5180 and MLV were titrated on represen-
tative HeLa cell clones expressing scrambled control (SC) or
Nup358 or transportin 3 (TRN-SR2) specific shRNA. Graphs
show the percentage of infected GFP positive cells per ng RT
measured at 48 hours post infection. The data are representative
of three independent experiments with three independent single
cell clones.
(PDF)
Figure S2 Validation of shRNA targeting efficiency. A,
Plasmid eGFPNup358 was co-transfected with vectors encoding
shRNAs against scrambled control (SC), TRN-SR2 or Nup358
into 293T cells. Transfected cells were analyzed by flow cytometry
and percentage of GFP-positive cells (left panels) as well as mean
fluorescence intensity (MFI) of GFP-positive cells (right panels) was
determined. B, Plasmid TRN-SR2-IRES-eGFP was co-transfect-
ed with indicated shRNA expression vectors into 293T and
analysis was performed as in A.
(PDF)
Figure S3 TRN-SR2 RNAi blocks HIV-1 at two steps.
HeLa cells stably transduced with vectors encoding shRNA
targeting scrambled control (SC), TRN-SR2 or Nup358 were
infected with HIV-1 GFP vector and grown for two weeks
before extraction of total DNA. As a control cells were inoculated
with boiled supernatant. Abundance of integrated provirus was
measured from 500 ng total DNA of two independent samples per
cell line by Taqman qPCR for GFP. Fold changes to infectivity on
EV cells are shown above the bars. TRN-SR2 RNAi reduced 2-
LTR circles by four-fold (Figure 1D), whereas reduction of
integrated provirus was 50-fold, suggesting that there are two
blocks in a canonical way, firstly at the step of nuclear entry and
secondly at the step of integration. Boiled controls were below
detectable levels.
(PDF)
Figure S4 CD4 expression measured by antiCD4
APC
staining. HeLa control cells (SC), or cells expressing Nup358 or
transportin 3 (TRN-SR2) specific shRNAs were transduced with
MiGRI-CD4-IRES-neo MLV-vector and subsequently G-418
selected. CD4 expression in drug-selected populations was analyzed
by staining with an antiCD4-antibody conjugated to APC as
described [59]. As a negative control (NC) we used untransduced
HeLa cells.
(PDF)
Figure S5 HIV-1 CA mutants are impaired in Nup358-
Cyp binding. CRFK cells expressing empty vector (EV) or
TRIMNup358 were infected with the indicated GFP encoding
VSV-G pseudotyped viral vectors and infectious titers per ng RT
were determined. Fold changes to infectivity on EV cells are shown
above the bars. The data are representative of two independent
experiments each performed withthree different vector doses (mean
and SE, n=2).
(PDF)
Figure S6 Amino acid alignment of sequences used in
the positive selection analysis. Nup358Cyp DNA sequences
from 12 different species [Rhesus macaque (M. mulatta), Human
(H. sapiens), Chimpanzee (P. troglodytes), Dog (C. familiaris), Cow (B.
taurus), Horse (E. caballus), Marmoset (C. jacchus), Mouse (M.
musculus), Rat (R. norvegicus), Opossum (M. domestica), Orangutan
(P. abelii) and Rabbit (O. cuniculus)] were aligned manually and
translated into amino acid sequences. Analysis of codon-specific
selective pressures using the algorithm Random Effect Likelihood
(REL) implemented on the online version of the HyPhy package
[28] was performed as previously described [27].
(PDF)
Figure S7 Integration targeting of wild type HIV-1 and
CA mutants. A, We sequenced 19,546 unique integration sites
by 454/Roche pyrosequencing and aligned them to the hg18
annotated human genome for analysis, as described [34–37]. We
examined the density of several genomic features near integration
sites, including relative gene density. Average of genes in a 1MB
window around the integration sites were determined and
compared to random controls for each virus. CypA/Nup358-
independent CA mutants G89V, P90A and HIV-1(SIVCA)
integrate in areas with higher gene density, whereas Nup358
and transportin 3-independent mutants N57A and N74D integrate
in areas of gene density comparable to random controls. B, Wild
type NL4.3 (Ba-L Env) or NL4.3 (Ba-L Env) bearing CA
mutations P90A or N74D were used to infect human MDM from
two donors in addition to those in Figure 4F at low multiplicity.
Cells were stained for Gag p24 at specific time points after
infection and infected colonies counted. Errors are standard error
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on independent donors.
(PDF)
Figure S8 Effect of CypA inhibition on Nup358 or
transportin3 RNAi sensitivity. HeLa cells expressing scram-
bled control (SC), Nup358 or transportin 3 (TRN-SR2) specific
shRNA were infected with a fixed dose of wild type or mutant
HIV-1 GFP in the presence of increasing concentrations of Cs (0–
10 mM). Percentage infection was measured 48 hours later by
detecting GFP positive cells using flow cytometry and plotted
against Cs concentration.
(PDF)
Figure S9 Effects of TRN-SR2 or Nup358 RNAi on HIV-1
Env pseudotyped vectors. HeLa cells stably expressing
scrambled control (SC), Nup358 or transportin 3 (TRN-SR2)
specific shRNA were transduced with MLV vector MiGRI-CD4-
IRES-neo and drug selected with G418. Similar CD4 expression
was determined by antiCD4
APC staining (Figure S4). Generated
cells were infected with HIV-1 GFP vectors that were pseudotyped
with HIV-1 Env derived from YU-2. Infectivity of wild type HIV-
1 (WT) was reduced similarly strongly as compared to VSV-G
pseudotyped virus. HIV-1 CA mutants P90A and N74D showed a
slightly increased sensitivity to both TRN-SR2 as well as Nup358
RNAi, suggesting envelope specific effects as suggested in a
previous study for TRN-SR2 [31].
(PDF)
Table S1 Effects of aphidicolin treatment. Shown are fold
reductions of infectious titers from graphs in Figure 3A. Left site of
the table shows fold reduction of wild type HIV-1 or CA mutant
infectious titer after aphidicolin (AC) treatment of HeLa cells
transduced with vector encoding shRNA for scrambled control,
Nup358 or TRN-SR2 as compared to untreated cells. Of note,
infectious titers of all viruses, apart from N57A were not
significantly changed in AC arrested cells as compared to
untreated cells. Right site of the table shows fold reduction of
infectious titers by Nup358 or TRN-SR2 RNAi as compared to
control RNAi in AC arrested or untreated HeLa cells. Of note, the
effect of Nup358 or TRN-SR2 RNAi on HIV-1 wild type virus
(WT) or CA mutants, except N57A, was similar in AC arrested
and untreated cells. N57A became slightly more sensitive to
Nup358 or TRN-SR2 RNAi in arrested cells. However, N57A
infectivity was reduced by ,100 fold after AC treatment,
suggesting that the 2–4 fold increased sensitivity to Nup358 or
TRN-SR2 RNAi is not significant.
(PDF)
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